Skip to Content
Publications

Cell-Line Development is Critical to the Future of Complex Therapeutics

Chang, Eric. BioProcess International, April 2025, pp. 20-23. https://secure.viewer.zmags.com/publication/0d260962#/0d260962/22.

Background

Eric Chang, MSc, from Bora Biologics discusses the critical role of cell-line engineering in biopharmaceutical production, particularly for complex therapeutics like bispecific antibodies. He highlights key requirements including cell-line stability, monoclonality, cost-effectiveness, and risk mitigation. Chang also explores challenges in developing cell lines for complex biologics and strategies for optimizing productivity, such as genetic engineering and codon optimization.

Abstract

Cell-line development (CLD) is a pivotal stage in biopharmaceutical production. Through the application of diverse techniques, biopharmaceutical companies can enhance the capacity, quality, and productivity of mammalian and microbial cell lines to generate a safe, stable, and abundant supply of biologics. However, as biotherapies increase in complexity, drug developers face new challenges in designing and implementing CLD processes that can ensure the efficient production of difficult-to-express protein therapeutics. Meanwhile, the industry is expanding beyond traditional monoclonal antibody (mAb) therapies, designing new innovative and complex biologics such as bispecific antibodies (bsAbs), engineered antibody fragments, and antibody-drug conjugates (ADCs).

View on BioProcess International

Bora Biologics

the logical choice

Join the ranks of biopharma pioneers who trust us.
Explore how we minimize risks and accelerate your success.

Partner with us

Client-Centric

100% commitment to supporting your success

We have been the client, bringing multiple biologics from IND to BLA. Your needs and goals are at the forefront of our approach. By involving you in every step of the process, we ensure transparency and alignment, reducing the likelihood of misunderstandings and ensuring the outcome meets your expectations.

Experience

14 years developing & manufacturing biologics

We have honed our ability to navigate complexities. Our track record from concept to commercialization means we can apply best practices and lessons learned, ensuring smoother project execution.

Expertise

125 seasoned scientists & regulatory professionals

Our team exudes deep knowledge and specialized skills. This expertise allows us to foresee potential challenges and implement proactive solutions, reducing the likelihood of setbacks.

Commercial-Ready

US FDA registered GMP manufacturing facility

We focus on delivering solutions that are ready for market. With clinical to commercial scale facilities consistently meeting compliance standards, we ensure your project is primed for success, minimizing the risk of costly revisions or delays.

Allied

access to global CDMO resources

Our partnership with Bora Pharmaceuticals provides additional resources and insights. This network enables us to leverage shared knowledge and expertise, further mitigating risks and accelerating the overall success of your project.